


Supplementary figure

Supplementary figure legend

Figure S1. The CIKs treatment protocol. CIKs, cytokine-induced killer cells; NPC, nasopharyngeal carcinoma; W, week.

Figure S1



Supplementary tables

Table S1. The EBV DNA level of the NPC patients between the control and CIK treatment groups in the T1/2 and T3/4 subgroups, respectively

EBV DNA (copies/mL)	T1/2 subgroup (n=61)			T3/4 subgroup (n=109)			P_3 0.614
	Control	CIK	P_1	Control	CIK	P_2	
			0.363			0.899	
< 4000	12	18		30	28		
\geq 4000	16	15		27	24		

P_1 comparison between the control and CIK groups in the T1/2 subgroup.

P_2 comparison between the control and CIK groups in the T3/4 subgroup.

P_3 comparison between the T1/2 and T3/4 subgroups.

Table S2. The EBV DNA level of the NPC patients between the control and CIK treatment groups in the II, III and IV subgroups, respectively

EBV DNA (copies/mL)	II subgroup (n=39)			III subgroup (n=93)			IV subgroup (n=38)			P_4
	Control	CIK	P_1	Control	CIK	P_2	Control	CIK	P_3	
			0.621			0.598			0.098	0.722
< 4000	8	10		26	24		8	12		
\geq 4000	11	10		20	23		12	6		

P_1 comparison between the control and CIK groups in the II subgroup.

P_2 comparison between the control and CIK groups in the III subgroup.

P_3 comparison between the control and CIK groups in the IV subgroup.

P_4 comparison between the II, III and IV subgroups.

Table S3. The distribution of clinical stage of the NPC patients between the EBV high and low groups

Clinical stage	EBV low group n = 88	EBV high group n = 82	<i>P</i>
			0.722
II	18	21	
III	50	43	
IV	20	18	